Airoldi M, Fazio M, Gandolfo S, Ozzello F, Pedani F
J Maxillofac Surg. 1985 Jun;13(3):111-5. doi: 10.1016/s0301-0503(85)80028-x.
Eighty-five patients (74 males, 11 females) with untreated squamous-cell carcinoma of the tongue (40 patients) and the floor of the mouth (45 patients) underwent a multidisciplinary treatment.
FOLLOW-UP: 6-72 months (median 52 months). T1-4N0M0 lesions (tongue; 32 patients; floor of mouth, 32 patients) were treated with cryosurgery (T1-2: 1-2 sessions, T3-4: 2-4 sessions) and contemporaneously with CMF (cyclophosphamide, methotrexate, fluorouracil) (T1-2: 2 courses; T3-4: 3 courses). 15-20 days after the end of cryo-chemotherapy the patients underwent TCT (T1: 50 Gy to the tumour and lymph nodes; T2-3-4: same with an extra dose of 10-15 Gy to the primary lesion). T1-4N1-3M0 patients (tongue: 8, floor of mouth: 13) received the same cryotherapy and chemotherapy, followed by surgery (13 extended suprahyoid dissections, 8 conservative laterocervical dissections, 1 RND). The actuarial survival rate of patients with tongue tumours after 6 years was 81.4% (N0 87.1%; N+ 60.0%). Four months after treatment, 35 patients had reached complete remission (CR). The probability of remaining in CR for 6 years was 53.6% (N0 56.1%; N+ 50.0%). For tumours of the floor of the mouth the actuarial survival rate was 55.2% (N0 56.5%; N+ 48.6%). Four months after treatment, 38 patients had reached CR. The probability of remaining in CR for 6 years was 59.9% (N0 61.5%; N+ 59.3%). A controlled study is recommended in the light of these results and the conservative nature of the protocol.
85例未经治疗的舌(40例)和口底(45例)鳞状细胞癌患者接受了多学科治疗。
6 - 72个月(中位时间52个月)。T1 - 4N0M0病变(舌部;32例患者;口底,32例患者)采用冷冻手术治疗(T1 - 2:1 - 2个疗程,T3 - 4:2 - 4个疗程),同时联合CMF(环磷酰胺、甲氨蝶呤、氟尿嘧啶)治疗(T1 - 2:2个疗程;T3 - 4:3个疗程)。冷冻化疗结束后15 - 20天,患者接受TCT治疗(T1:肿瘤及淋巴结照射50 Gy;T2 - 3 - 4:相同剂量,原发灶额外增加10 - 15 Gy)。T1 - 4N1 - 3M0患者(舌部:8例,口底:13例)接受相同的冷冻治疗和化疗,随后进行手术(13例扩大的舌骨上区清扫术,8例保守性颈侧区清扫术,1例根治性颈清扫术)。舌部肿瘤患者6年后的精算生存率为81.4%(N0为87.1%;N+为60.0%)。治疗4个月后,35例患者达到完全缓解(CR)。6年维持CR的概率为53.6%(N0为56.1%;N+为50.0%)。口底肿瘤的精算生存率为55.2%(N0为56.5%;N+为48.6%)。治疗4个月后,38例患者达到CR。6年维持CR的概率为59.9%(N0为61.5%;N+为59.3%)。鉴于这些结果和治疗方案的保守性,建议进行对照研究。